Transcranial magnetic stimulation (tms) for major depression
Depression and Anxiety, 06/12/2012Carpenter LL et al.
Outcomes demonstrated response and adherence rates similar to research populations. These data indicate that transcranial magnetic stimulation is an effective treatment for those unable to benefit from initial antidepressant medication.
Forty-two US-based clinical TMS practice sites treated 307 outpatients with Major Depressive Disorder (MDD), and persistent symptoms despite antidepressant pharmacotherapy.
Treatment was based on the labeled procedures of the approved TMS device.
Assessments were performed at baseline, week 2, at the point of maximal acute benefit, and at week 6 when the acute course extended beyond 6 weeks.
The primary outcome was change in the Clinician Global Impressions-Severity of Illness from baseline to end of acute phase.
Secondary outcomes were change in continuous and categorical outcomes on self-report depression scales (9-Item Patient Health Questionnaire [PHQ-9], and Inventory of Depressive Symptoms-Self Report [IDS-SR]).
Patients had a mean ± SD age of 48.6 ± 14.2 years and 66.8% were female.
Patients received an average of 2.5 (± 2.4) antidepressant treatments of adequate dose and duration without satisfactory improvement in this episode.
There was a significant change in CGI-S from baseline to end of treatment (-1.9 ± 1.4, P < .0001).
Clinician-assessed response rate (CGI-S) was 58.0% and remission rate was 37.1%.
Patient-reported response rate ranged from 56.4 to 41.5% and remission rate ranged from 28.7 to 26.5%, (PHQ-9 and IDS-SR, respectively).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.